Biological tools for npc population screening and disease monitoring

Advances in Experimental Medicine and Biology

Volumn 778, Issue , 2013, Pages 101-117

  Gourzones, Claire ^a   Ferrand, François Régis ^a   Vérillaud, Benjamin ^a   Busson, Pierre ^a  

^a CNRS   (France)

Author keywords

Biological tool; Nasopharyngeal brushing; Nasopharyngeal carcinoma; Nasopharyngeal carcinoma patient; Undifferentiated nasopharyngeal carcinoma

Indexed keywords

CCCL20 PROTEIN; ECALECTIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; STEFIN A; TUMOR MARKER; UNCLASSIFIED DRUG; VIRAL PROTEIN; VIRUS ANTIBODY; VIRUS DNA; VIRUS RNA;

ANTIBODY DETECTION; ANTIBODY TITER; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESEARCH; CANCER SCREENING; CANCER SIZE; CANCER THERAPY; CARCINOGENESIS; COST EFFECTIVENESS ANALYSIS; DISEASE MARKER; EARLY DIAGNOSIS; EPSTEIN BARR VIRUS INFECTION; FOLLOW UP; HUMAN; MASS SCREENING; MOLECULAR DIAGNOSIS; NASOPHARYNX; NASOPHARYNX CARCINOMA; NONHUMAN; NOSE SMEAR; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEROLOGY; TREATMENT RESPONSE; TUMOR INVASION; VIRUS LOAD;

EID: 84879917365     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5947-7_7     Document Type: Chapter

References (100)

1. Old LJ, Boyse EA, Oettgen HF et al. Precipitating antibody in human serum to an antigen present in cultured burkitt’s lymphoma cells. Proc Natl Acad Sci USA 1966; 56(6):1699-1704.
2. Henle W, Henle G, Ho HC et al. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst 1970; 44(1):225-231.
3. Ho HC, Kwan HC, Ng MH et al. Serum IgA antibodies to Epstein-Barr virus capsid antigen preceding symptoms of nasopharyngeal carcinoma. Lancet 1978; 1(8061):436.
4. Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976; 17(1):1-7.
5. Wara WM, Wara DW, Phillips TL et al. Elevated IGA in carcinoma of the nasopharynx. Cancer 1975; 35(5):1313-1315.
6. Desgranges C, de-The G. Epstein-Barr virus specific IgA serum antibodies in nasopharyngeal and other respiratory carcinomas. Int J Cancer 1979; 24(5):555-559.
7. Chien YC, Chen JY, Liu MY et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 2001; 345(26):1877-1882.
8. Fachiroh J, Stevens SJ, Haryana SM et al. Combination of Epstein-Barr virus scaffold (BdRF1/VCA-p40) and small capsid protein (BFRF3/VCA-p18) into a single molecule for improved serodiagnosis of acute and malignant EBV-driven disease. J Virol Methods 2010; 169(1):79-86.
9. Joab I, Nicolas JC, Schwaab G et al. Detection of anti-Epstein-Barr-virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma. Int J Cancer 1991; 48(5):647-649.
10. Xu J, Ahmad A, Blagdon M et al. The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases. Int J Cancer 1998; 79(5):481-486.
11. Yu KJ, Hsu WL, Pfeiffer RM et al. Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families. Clin Cancer Res 2011; 17(7):1906-1914.
12. Zeng Y, Zhang LG, Wu YC et al. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer 1985; 36(5):545-547.
13. Ji MF, Wang DK, Yu YL et al. Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br J Cancer 2007; 96(4):623-630.
14. Cao SM, Liu Z, Jia WH et al. Fluctuations of epstein-barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up. PloS One 2011; 6(4):e19100.
15. de-The G, Ho JH, Ablashi DV et al. Nasopharyngeal carcinoma. IX. Antibodies to EBNA and correlation with response to other ebv antigens in chinese patients. Int J Cancer 1975; 16(5):713-721.
16. Xu J, Ahmad A, D’Addario M et al. Analysis and significance of anti-latent membrane protein-1 antibodies in the sera of patients with EBV-associated diseases. J Immunol 2000; 164(5):2815-2822.
17. Frech B, Zimber-Strobl U, Suentzenich KO et al. Identification of Epstein-Barr virus terminal protein 1 (TP1) in extracts of four lymphoid cell lines, expression in insect cells, and detection of antibodies in human sera. J Virol 1990; 64(6):2759-2767.
18. Paramita DK, Fatmawati C, Juwana H et al. Humoral immune responses to Epstein-Barr virus encoded tumor associated proteins and their putative extracellular domains in nasopharyngeal carcinoma patients and regional controls. J Med Virol 2011; 83(4):665-678.
19. Hoebe EK, Hutajulu SH, van Beek J et al. Purified hexameric Epstein-Barr virus-encoded BARF1 protein for measuring anti-BARF1 antibody responses in nasopharyngeal carcinoma patients. Clin Vaccine Immunol 2011; 18(2):298-304.
20. Fachiroh J, Schouten T, Hariwiyanto B et al. Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects. J Infect Dis 2004; 190(1):53-62.
21. Karray H, Ayadi W, Fki L et al. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. J Med Virol 2005; 75(4):593-602.
22. Littler E, Baylis SA, Zeng Y et al. Diagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins. Lancet 1991; 337(8743):685-689.
23. Pickard A, Chen CJ, Diehl SR et al. Epstein-Barr virus seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan. Int J Cancer 2004; 111(1):117-123.
24. Gu AD, Lu LX, Xie YB et al. Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology. J Transl Med 2009; 7:73.
25. Fachiroh J, Paramita DK, Hariwiyanto B et al. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1-and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening. J Clin Microbiol 2006; 44(4):1459-1467.
26. Paramita DK, Fachiroh J, Haryana SM et al. Two-step Epstein-Barr virus immunoglobulin A enzyme-linked immunosorbent assay system for serological screening and confirmation of nasopharyngeal carcinoma. Clin Vaccine Immunol 2009; 16(5):706-711.
27. Mutirangura A, Pornthanakasem W, Theamboonlers A et al. Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. Clin Cancer Res 1998; 4(3):665-669.
28. Lo YM, Chan LY, Lo KW et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999; 59(6):1188-1191.
29. Lo YM, Chan LY, Chan AT et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999; 59(21):5452-5455.
30. Chan KC, Lo YM. Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12(6):489-496.
31. Lin JC, Wang WY, Chen KY et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350(24):2461-2470.
32. Wei WI, Yuen AP, Ng RW et al. Quantitative analysis of plasma cell-free Epstein-Barr virus DNA in nasopharyngeal carcinoma after salvage nasopharyngectomy: a prospective study. Head Neck 2004; 26(10):878-883.
33. Liu Y, Fang Z, Liu L et al. Detection of Epstein-Barr virus DNA in serum or plasma for nasopharyngeal cancer: a meta-analysis. Genet Test Mol Biomarkers 2011; 15(7-8):495-502.
34. Stevens SJ, Verkuijlen SA, Hariwiyanto B et al. Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. J Clin Microbiol 2005; 43(7):3066-3073.
35. Rowe DT, Webber S, Schauer EM et al. Epstein-Barr virus load monitoring: its role in the prevention and management of posttransplant lymphoproliferative disease. Transpl Infect Dis 2001; 3(2):79-87.
36. Shao JY, Zhang Y, Li YH et al. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma. Anticancer Res 2004; 24(6):4059-4066.
37. Wang WY, Chien YC, Jan JS et al. Consistent sequence variation of Epstein-Barr virus nuclear antigen 1 in primary tumor and peripheral blood cells of patients with nasopharyngeal carcinoma. Clin Cancer Res 2002; 8(8):2586-2590.
38. Hsiao JR, Jin YT, Tsai ST. Detection of cell free Epstein-Barr virus DNA in sera from patients with nasopharyngeal carcinoma. Cancer 2002; 94(3):723-729.
39. Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61(4):1659-1665.
40. Chan KC, Zhang J, Chan AT et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 2003; 63(9):2028-2032.
41. Ryan JL, Fan H, Glaser SL et al. Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. J Mol Diagn 2004; 6(4):378-385.
42. O TM, Yu G, Hu K et al. Plasma Epstein-Barr virus immunoglobulin A and DNA for nasopharyngeal carcinoma screening in the United States. Otolaryngol Head Neck Surg 2007; 136(6):992-997.
43. Lay ML, Lucas RM, Ratnamohan M et al. Measurement of Epstein-Barr virus DNA load using a novel quantification standard containing two EBV DNA targets and SYBR Green I dye. Virol J 2010; 7:252.
44. Lin JC, Wang WY, Liang WM et al. Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007; 68(5):1342-1348.
45. To EW, Chan KC, Leung SF et al. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res 2003; 9(9):3254-3259.
46. Chan AT, Lo YM, Zee B et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002; 94(21):1614-1619.
47. Le QT, Jones CD, Yau TK et al. A comparison study of different PCR assays in measuring circulating plasma epstein-barr virus DNA levels in patients with nasopharyngeal carcinoma. Clin Cancer Res 2005; 11(16):5700-5707.
48. Wang WY, Twu CW, Chen HH et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res 2010; 16(3):1016-1024.
49. Hsu CL, Chang KP, Lin CY et al. Plasma epstein-barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma. Head and Neck 2011.
50. Lo YM, Leung SF, Chan LY et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res 2000; 60(9):2351-2355.
51. Gourzones C, Gelin A, Bombik I et al. Extra-cellular release and blood diffusion of BART viral micro-RNAs produced by EBV-infected nasopharyngeal carcinoma cells. Virology Journal 2010; 7:271.
52. Wong AM, Kong KL, Tsang JW et al. Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. Cancer 2011.
53. Lo KW, Lo YM, Leung SF et al. Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. Clin Chem 1999; 45(8 Pt 1):1292-1294.
54. Vickers KC, Palmisano BT, Shoucri BM et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011; 13(4):423-433.
55. Arroyo JD, Chevillet JR, Kroh EM et al. Argonaute2 complexes carry a population of circulating micro RNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108(12):5003-5008.
56. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecologic Oncology 2008; 110(1):13-21.
57. Hunter MP, Ismail N, Zhang X et al. Detection of microRNA expression in human peripheral blood microvesicles. PloS One 2008; 3(11):e3694.
58. Schorey JS, Bhatnagar S. Exosome function: from tumor immunology to pathogen biology. Traffic 2008; 9(6):871-881.
59. Castellana D, Toti F, Freyssinet JM. Membrane microvesicles: macromessengers in cancer disease and progression. Thromb Res 2010; 125 Suppl 2:S84-88.
60. Valadi H, Ekstrom K, Bossios A et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9(6):654-659.
61. Al-Nedawi K, Meehan B, Rak J. Microvesicles: messengers and mediators of tumor progression. Cell Cycle 2009; 8(13):2014-2018.
62. Houali K, Wang X, Shimizu Y et al. A new diagnostic marker for secreted Epstein-Barr virus encoded LMP1 and BARF1 oncoproteins in the serum and saliva of patients with nasopharyngeal carcinoma. Clin Cancer Res 2007; 13(17):4993-5000.
63. Meckes DG, Jr., Shair KH, Marquitz AR et al. Human tumor virus utilizes exosomes for intercellular communication. Proc Natl Acad Sci USA 2010; 107(47):20370-20375.
64. Wong TS, Kwong DL, Sham JS et al. Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clin Cancer Res 2004; 10(7):2401-2406.
65. Caggiari L, Guidoboni M, Vaccher E et al. High serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: pathogenic and clinical relevance. Infect Agent Cancer 2007; 2:5.
66. Rousselet G, Bachouchi M, Busson P et al. Clinical implications of the serum level of CD23 in patients with undifferentiated nasopharyngeal carcinoma. J Clin Oncol 1993; 11(11):2143-2149.
67. Chang KP, Hao SP, Chang JH et al. Macrophage inflammatory protein-3alpha is a novel serum marker for nasopharyngeal carcinoma detection and prediction of treatment outcomes. Clin Cancer Res 2008; 14(21):6979-6987.
68. Xu J, Menezes J, Prasad U et al. Elevated serum levels of transforming growth factor beta1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients. International Journal of Cancer 1999; 84(4):396-399.
69. Li J, Zeng XH, Mo HY et al. Functional Inactivation of EBV-Specific T-Lymphocytes in Nasopharyngeal Carcinoma: Implications for Tumor Immunotherapy. PloS One 2007; 2(11):e1122.
70. Li J, Chen QY, Mo H et al. Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy. Int J Biol Sci 2011; 7(5):607-617.
71. Chang KP, Chang YT, Wu CC et al. Multiplexed immunobead-based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival. Head Neck 2011; 33(6):886-897.
72. Chang KP, Wu CC, Chen HC et al. Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: potential usage of cystatin A for predicting nodal stage and poor prognosis. Proteomics 2010; 10(14):2644-2660.
73. Keryer-Bibens C, Pioche-Durieu C, Villemant C et al. Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer 2006; 6:283.
74. Klibi J, Niki T, Riedel A et al. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 2009; 113(9):1957-1966.
75. Zhu C, Anderson AC, Schubart A et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6(12):1245-1252.
76. Pioche-Durieu C, Keryer C, Souquere S et al. In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin. J Virol 2005; 79(21):13326-13337.
77. Feinmesser R, Miyazaki I, Cheung R et al. Diagnosis of nasopharyngeal carcinoma by DNA amplification of tissue obtained by fine-needle aspiration. N Engl J Med 1992; 326(1):17-21.
78. Oudejans JJ, Harijadi H, Kummer JA et al. High numbers of granzyme B/CD8-positive tumour-infiltrating lymphocytes in nasopharyngeal carcinoma biopsies predict rapid fatal outcome in patients treated with curative intent. J Pathol 2002; 198(4):468-475.
79. Qian CN, Guo X, Cao B et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 2002; 62(2):589-596.
80. Khabir A, Karray H, Rodriguez S et al. EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas. Virol J 2005; 2(1):39.
81. Benders AA, Tang W, Middeldorp JM et al. Epstein-Barr virus latent membrane protein 1 is not associated with vessel density nor with hypoxia inducible factor 1 alpha expression in nasopharyngeal carcinoma tissue. Head Neck Pathol 2009; 3(4):276-282.
82. Zhao Y, Wang Y, Zeng S et al. LMP1 expression is positively associated with metastasis of nasopharyngeal carcinoma: evidence from a meta-analysis. J Clin Pathol 2012; 65(1):41-45.
83. Tsuji A, Wakisaka N, Kondo S et al. Induction of receptor for advanced glycation end products by EBV latent membrane protein 1 and its correlation with angiogenesis and cervical lymph node metastasis in nasopharyngeal carcinoma. Clin Cancer Res 2008; 14(17):5368-5375.
84. Smith C, Tsang J, Beagley L et al. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res 2012; 72(5):1116-1125.
85. Yip KW, Shi W, Pintilie M et al. Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res 2006; 12(19):5726-5732.
86. Oudejans JJ, Harijadi A, Cillessen SA et al. Absence of caspase 3 activation in neoplastic cells of nasopharyngeal carcinoma biopsies predicts rapid fatal outcome. Mod Pathol 2005; 18(7):877-885.
87. Wang HY, Sun BY, Zhu ZH et al. Eight-signature classifier for prediction of nasopharyngeal [corrected] carcinoma survival. J Clin Oncol 2011; 29(34):4516-4525.
88. Sheen TS, Ko JY, Chang YL et al. Nasopharyngeal swab and PCR for the screening of nasopharyngeal carcinoma in the endemic area: a good supplement to the serologic screening. Head Neck 1998; 20(8):732-738.
89. Billings KR, Rollins NK, Timmons C et al. Infected neonatal cervical thymic cyst. Otolaryngol Head Neck Surg 2000; 123(5):651-654.
90. Hao SP, Tsang NM, Chang KP. Screening nasopharyngeal carcinoma by detection of the latent membrane protein 1 (LMP-1) gene with nasopharyngeal swabs. Cancer 2003; 97(8):1909-1913.
91. Stevens SJ, Verkuijlen SA, Hariwiyanto B et al. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA. International Journal of Cancer. Int J Cancer 2006; 119(3):608-614.
92. Altman DG, Bland JM. Diagnostic tests 2: Predictive values. BMJ 1994; 309(6947):102.
93. Hutajulu SH, Indrasari SR, Indrawati LP et al. Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population. Mol Cancer 2011; 10:48.
94. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell 2004; 5(5):423-428.
95. Leung SF, Tam JS, Chan AT et al. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem 2004; 50(2):339-345.
96. Leung SF, Zee B, Ma BB et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006; 24(34):5414-5418.
97. de-Vathaire F, Sancho-Garnier H, de-The H et al. Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): a multicenter follow-up study. Int J Cancer 1988; 42(2):176-181.
98. Twu CW, Wang WY, Liang WM et al. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2007; 67(1):130-137.
99. Wang WY, Twu CW, Lin WY et al. Plasma Epstein-Barr virus DNA screening followed by (1) F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma. Cancer 2011; 117(19):4452-4459.
100. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105(30):10513-10518.